NO924844L - CANCER-ASSOCIATED SCM RECOGNITION FACTOR, PROCEDURE FOR ITS MANUFACTURING AND USE OF THE FACTOR - Google Patents
CANCER-ASSOCIATED SCM RECOGNITION FACTOR, PROCEDURE FOR ITS MANUFACTURING AND USE OF THE FACTORInfo
- Publication number
- NO924844L NO924844L NO92924844A NO924844A NO924844L NO 924844 L NO924844 L NO 924844L NO 92924844 A NO92924844 A NO 92924844A NO 924844 A NO924844 A NO 924844A NO 924844 L NO924844 L NO 924844L
- Authority
- NO
- Norway
- Prior art keywords
- factor
- scm
- cancer
- useful
- scm factor
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
Abstract
En cancer-gjenkjennelsesfaktor (SCM faktor) nyttig ved gjennomføringen av testen med strukturerthet av den cyto- plasmiske matriks (SCM) som er blitt isolert, renset til hovedsakelig homogenitet og karakterisert, og fremgangsmåter for dens anvendelse er beskrevet. Faktoren er et peptid med minst 9 aminosyrerester inkluderende en kjernesekvens med 9 aminosyrerester med en amfipatisitetsprofil hovedsakelig ekvivalent med sekvensen F-L-M-I-D-Q-N-T-K og frembringer i det minste en 10 % nedsettelse i den intracellulære fluore- scens-polarisasjonsverdi av SCM-responderende lymfocytter fra donorer som lider av cancer. En syntetisk SCM faktor som representerer en konsensussekvens av M-I-P-P-E-V-K-F-N-K-P-F- V-F-L-M-I-D-Q-N-T-K-V-P-L-F-M-G-K er fullt aktiv. Anti- stoffer spesifikke for SCM faktor er nyttige ved immuno- analyser som kan påvise faktoren, inkluderende påvisning i cancerceller dyrket in vitro. SCM faktoren er nyttig for screening av blodprøver og andre kroppsvæsker eller celle- aspirater for nærvær av malignans i donoren. Det multiple virkningsspektrum av SCM faktoren inkluderer cancerformering og invasjons-fremming, såvel som inhibering av vertens immun-forsvarsmekanismer og syntese av SCM faktor i cancer- celler, representerer et nytt mål for cancerbehandling. Metoder for reduksjon av in vivo aktivitet av SCM faktoren, som dialyse eller antistoffnøytralisasjon, kan også være nyttig ved behandling av cancer.A cancer recognition factor (SCM factor) useful in conducting the test of structure of the cytoplasmic matrix (SCM) that has been isolated, purified to substantially homogeneity and characterized, and methods for its use are described. The factor is a peptide having at least 9 amino acid residues including a core sequence of 9 amino acid residues with an amphipatity profile substantially equivalent to the sequence FLMIDQNTK and generating at least a 10% reduction in the intracellular fluorescence polarization value of SCM-responsive lymphocytes from lymphocytes. . A synthetic SCM factor representing a consensus sequence of M-I-P-P-E-V-K-F-N-K-P-F-V-F-L-M-I-D-Q-N-T-K-V-P-L-F-M-G-K is fully active. Antibodies specific for SCM factor are useful in immunoassays that can detect the factor, including detection in cancer cells grown in vitro. The SCM factor is useful for screening blood samples and other body fluids or cell aspirates for the presence of malignancy in the donor. The multiple spectrum of action of the SCM factor includes cancer proliferation and invasion promotion, as well as inhibition of the host's immune defense mechanisms and synthesis of SCM factor in cancer cells, represent a new target for cancer treatment. Methods for reducing the in vivo activity of the SCM factor, such as dialysis or antibody neutralization, may also be useful in the treatment of cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/539,686 US5270171A (en) | 1987-03-06 | 1990-06-18 | Cancer-associated SCM-recognition factor, preparation and method of use |
| PCT/US1991/004334 WO1991019736A2 (en) | 1990-06-18 | 1991-06-18 | Cancer-associated scm-recognition factor, preparation and method of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO924844D0 NO924844D0 (en) | 1992-12-15 |
| NO924844L true NO924844L (en) | 1993-02-16 |
Family
ID=26783212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO92924844A NO924844L (en) | 1990-06-18 | 1992-12-15 | CANCER-ASSOCIATED SCM RECOGNITION FACTOR, PROCEDURE FOR ITS MANUFACTURING AND USE OF THE FACTOR |
Country Status (1)
| Country | Link |
|---|---|
| NO (1) | NO924844L (en) |
-
1992
- 1992-12-15 NO NO92924844A patent/NO924844L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO924844D0 (en) | 1992-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL98455A (en) | Cancer-associated scm-recognition factor and its method of use | |
| Klein et al. | Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines | |
| Weiss et al. | Demonstration of a saturable binding site for thyrotropin in Yersinia enterocolitica | |
| EP0159276A2 (en) | Substantially purified tumor growth inhibitory factor (tif) | |
| Burger et al. | Human transfer factor: effects on lymphocyte transformation | |
| Mansoor et al. | Endothelin-induced collagen remodeling in experimental pulmonary hypertension | |
| Burger et al. | Human transfer factor: fractionation and biologic activity | |
| Soutter et al. | Problems in the surgical management of thymic tumors | |
| Herberman et al. | Cellular Immune Reactions to Human Leu-kemia¹, 2 | |
| Liapi-Avgeri et al. | Glomus tumor: A histological, histochemical and immunohistochemical study of the various types | |
| Glynn et al. | Immunological aspects of rheumatoid disease: a review | |
| Geller et al. | Electrophoresis of saliva | |
| NO924844L (en) | CANCER-ASSOCIATED SCM RECOGNITION FACTOR, PROCEDURE FOR ITS MANUFACTURING AND USE OF THE FACTOR | |
| Cercek et al. | Induction of PHA response in mouse bone marrow cells by thymic extracts as studied by changes in the structuredness of cytoplasmic matrix | |
| Shohat et al. | Immunosuppressive activity and polyamine levels of seminal plasma in azo-ospermic, oligospermic, and normospermic men | |
| Brown et al. | Cell surface charge alterations occurring during dimethylsulfoxide-induced erythrodifferentiation of Friend leukemia cells | |
| McCabe et al. | Immunosuppression by human skin cancers | |
| Ellis et al. | Immunological estimation of a component of complement | |
| EP0357637B1 (en) | General cancer-associated scm-recognition factor, preparation and method of use | |
| Riesz et al. | Determination of free radicals in gamma irradiated proteins | |
| Naruse et al. | Immunoreactive thymosin α1 in human thymus and thymoma | |
| Fujii et al. | Oligo-2', 5'-adenylate synthetase activity in peripheral blood mononuclear leukocytes in various diseases | |
| Elhilali et al. | In vitro cytotoxicity studies in bladder and renal cell cancer | |
| Cortesina et al. | Production of leukocyte migration inhibition factor by lymphocytes of larynx cancer patients stimulated by laryngeal carcinoma solubilized membrane antigens | |
| Darnule et al. | Antiserum to surface antigens as a marker for cultured rat lung endothelial cells (1) |